SHAPING OUR FUTURE TOGETHER

For over 25 years, TMS has been a responsive and empathetic servant to the mast cell disease community. As we reflect on our accomplishments and the lessons learned throughout our history, we know TMS has helped advance both the clinical and scientific boundaries of mast cell disease care and treatment options.

In 2017, TMS removed barriers and provided open-access to our services, education, and resources. And in 2020, we made strides even further by changing our organizational name to be reflective of our inclusivity of serving every patient suffering from any type of mast cell disease. Mast cell disease(s) (MCD) is the term used by mast cell specialists in the US and internationally for all mast cell diseases. This covers each variant: systemic mastocytosis (SM), cutaneous mastocytosis (CM), smoldering mastocytosis (SSM), advanced disease variants, mast cell activation syndrome (MCAS) and hereditary alpha tryptasemia (HaT). The MCD diagnostic consensus guidelines were developed by the World Health Organization (WHO), European Competence Network on Mastocytosis (ECNM) and the American Initiative in Mast Cell Diseases (AIM).

Today, as we look forward to the next three years, we remain deeply committed to patients first and working to educate patients, families and physicians, and research to find better treatment options and ultimately a cure. Our six strategic pillars are grounded by our mission and developed based on a series of interviews from patients, caregivers, volunteers, stakeholders and our recent needs assessment involving approximately 9,000 members to address increased patient impact and commitment to growth objectives. This strategic plan embodies our continuing commitment to listen to the diverse voices of our community, strengthen our partnerships with other organizations, and share findings and benefits from our work.
Our Strategies

Patient Programs
- Increase access to direct service, events, education, and experiences that enrich lives affected by mast cell diseases.
- Design pathway models and processes to meet patient needs.
- Promote a culture where patients come first in all we do.

Physician Education
- Establish nationally recognized model of education to increase physicians’ knowledge and treatment of mast cell diseases leading to increased access to care.

Research Grant Making
- Annually allocate up to 25% of unrestricted net revenue to support the funding of research grants on an annual basis.

Patient Centered Research
- Expand and engage in patient centered research that shares the patient voice, needs, and leads to better quality of life.
- Share current and leading peer-reviewed research and clinical publications.

Advocacy & Collaborations
- Increase awareness of the healthcare needs.
- Enhance existing and seek new strategic collaborative partnerships that enhance services, resources, and research.
- Build community trust and transparency.

Governance & Financial Sustainability
- Be adaptive and responsive to grow diversified revenue to met our mission.
- Commit to Board growth, expansion, and diversity.

Thank you to the many groups and individuals who shared ideas and input over a six-month period of strategic plan development. This plan belongs to all of you.